Sentinel™ Trial: A Prospective Study Evaluating the Performance and Clinical Benefit of Personalized ctDNA-based MRD Testing to Detect Recurrence and Monitor Treatment Response in Patients With Solid Tumors

You may be eligible if

• 1. Male or female participants ≥ 18 years of age;
• 2. Confirmed diagnosis of a stage 1-3 solid tumor;
• 3. Curative surgery or definitive therapy (e.g., chemoradiation, stereotactic body radiation therapy \[SBRT\]) completed \<5 years ago without any current evidence of radiographical or biochemical recurrence, or planned within 28 days of consent;
• 4. Surplus formalin fixed paraffin embedded tumor specimen available;
• 5. Able to tolerate venipuncture for blood draws;
• 6. Primary diagnosis is not glioma or CNS disease;
• 7. Both the tumor tissue sample and blood sample pass the quantity and quality parameters to allow for a successful MRD test result.